RU2417077C2 - Способ лечения чрезмерной дневной сонливости (варианты) - Google Patents

Способ лечения чрезмерной дневной сонливости (варианты) Download PDF

Info

Publication number
RU2417077C2
RU2417077C2 RU2008100019/15A RU2008100019A RU2417077C2 RU 2417077 C2 RU2417077 C2 RU 2417077C2 RU 2008100019/15 A RU2008100019/15 A RU 2008100019/15A RU 2008100019 A RU2008100019 A RU 2008100019A RU 2417077 C2 RU2417077 C2 RU 2417077C2
Authority
RU
Russia
Prior art keywords
sleep
enantiomer
administration
dose
compounds
Prior art date
Application number
RU2008100019/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2008100019A (ru
Inventor
Абдаллах АХНАОУ (BE)
Абдаллах АХНАОУ
Вильгельмус Х. И. М. ДРИНКЕНБУРГ (NL)
Вильгельмус Х. И. М. ДРИНКЕНБУРГ
Джозеф ПАЛУМБО (US)
Джозеф ПАЛУМБО
Джонатан СПОРН (US)
Джонатан СПОРН
Original Assignee
Ск Холдингз Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37085728&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2417077(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ск Холдингз Ко., Лтд. filed Critical Ск Холдингз Ко., Лтд.
Publication of RU2008100019A publication Critical patent/RU2008100019A/ru
Application granted granted Critical
Publication of RU2417077C2 publication Critical patent/RU2417077C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2008100019/15A 2005-06-08 2006-06-07 Способ лечения чрезмерной дневной сонливости (варианты) RU2417077C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68863805P 2005-06-08 2005-06-08
US60/688,638 2005-06-08

Publications (2)

Publication Number Publication Date
RU2008100019A RU2008100019A (ru) 2009-07-20
RU2417077C2 true RU2417077C2 (ru) 2011-04-27

Family

ID=37085728

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2008100019/15A RU2417077C2 (ru) 2005-06-08 2006-06-07 Способ лечения чрезмерной дневной сонливости (варианты)

Country Status (17)

Country Link
US (8) US8440715B2 (https=)
EP (1) EP1890684B1 (https=)
JP (1) JP5024635B2 (https=)
KR (1) KR101335941B1 (https=)
CN (1) CN101217949B (https=)
AU (1) AU2006254899B2 (https=)
BE (1) BE2020C004I2 (https=)
BR (1) BRPI0613697A2 (https=)
CA (1) CA2611713C (https=)
DK (1) DK1890684T3 (https=)
ES (1) ES2435403T3 (https=)
FR (1) FR20C1014I2 (https=)
NL (1) NL301037I2 (https=)
PL (1) PL1890684T3 (https=)
RU (1) RU2417077C2 (https=)
TW (2) TWI419681B (https=)
WO (1) WO2006133393A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2435403T3 (es) 2005-06-08 2013-12-19 Sk Biopharmaceuticals Co., Ltd. Tratamiento de trastornos del sueño y vigilia
ES2344469T3 (es) * 2005-06-22 2010-08-27 Sk Holdings Co., Ltd. Tratamiento de disfuncion sexual.
KR102173587B1 (ko) * 2009-06-22 2020-11-04 에스케이바이오팜 주식회사 피로의 치료 또는 예방 방법
US8232315B2 (en) * 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
US8895609B2 (en) * 2009-11-06 2014-11-25 Sk Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
MX350745B (es) * 2009-11-06 2017-09-14 Sk Biopharmaceuticals Co Ltd * El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia.
US8623913B2 (en) * 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) * 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US9359290B2 (en) * 2013-03-13 2016-06-07 Jazz Pharmaceuticals International Iii Limited Treatment of cataplexy
KR102309836B1 (ko) 2013-07-18 2021-10-12 에스케이바이오팜 주식회사 비만의 치료
TWI698415B (zh) * 2014-02-28 2020-07-11 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
US10888542B2 (en) 2014-02-28 2021-01-12 Sk Biopharmaceuticals Co., Ltd. Aminocarbonylcarbamate compounds
WO2016061488A1 (en) 2014-10-17 2016-04-21 Concert Pharmaceuticals, Inc. Amine reuptake inhibitors
JP6466792B2 (ja) * 2015-07-03 2019-02-06 エスケー バイオファーマスティカルズ カンパニー リミテッド 注意欠陥／多動性障害（ａｄｈｄ）の治療方法
TWI637765B (zh) * 2016-05-10 2018-10-11 台灣共振波研發股份有限公司 Soothing device for attention deficit hyperactivity disorder
ES2970887T3 (es) 2016-09-06 2024-05-31 Axsome Malta Ltd Forma de solvato de carbamato de (R)-2-amino-3-fenilpropilo
US10195151B2 (en) * 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
EP4316592A3 (en) 2016-10-06 2024-05-01 Axsome Malta Ltd. Carbamoyl phenylalaninol compounds and uses thereof
AU2018278332B2 (en) 2017-06-02 2022-05-19 Jazz Pharmaceuticals Ireland Limited Methods and compositions for treating excessive sleepiness
KR102643275B1 (ko) * 2017-07-31 2024-03-04 재즈 파마슈티칼즈 아일랜드 리미티드 카바모일 페닐알라니놀 유사체 및 이의 용도
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
US11033214B1 (en) * 2020-05-19 2021-06-15 United Arab Emirates University Wearable eye tracking system
KR102390194B1 (ko) 2020-08-03 2022-04-25 셀라이온바이오메드 주식회사 페닐알킬 카바메이트 화합물을 포함하는 Kca3.1채널 매개질환 치료용 조성물
AU2023375326A1 (en) * 2022-11-07 2025-05-22 Axsome Therapeutics Compositions and methods for treating insomnia
WO2024118904A1 (en) * 2022-11-30 2024-06-06 Axsome Therapeutics Methods and compositions for improving driving performance
KR20260033050A (ko) 2023-06-29 2026-03-10 액섬 테라퓨틱스, 인크. 수유 여성에게 솔리암페톨을 투여하는 방법
WO2025165760A1 (en) * 2024-01-29 2025-08-07 Axsome Therapeutics, Inc. Phenylalkylamino carbamates for use in the treatment of attention deficit/hyperactivity disorder

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2171674C2 (ru) * 1994-10-06 2001-08-10 Сефалон, Инк. Модафинил с определенным размером частиц

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2939660A1 (de) 1979-09-29 1981-04-16 Basf Ag, 6700 Ludwigshafen Neue carbamate, ihre herstellung und diese enthaltende pharmazeutische zubereitungen
NZ260667A (en) 1993-06-10 1997-05-26 Lilly Co Eli Preventing emesis or treating sexual dysfunction using tetrahydrobenz[cd]indole 6-carboxamides
KR100197892B1 (ko) 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
KR0173862B1 (ko) 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
US5756817C1 (en) * 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
EP0873308B1 (en) * 1996-10-10 2002-01-02 SK Corporation O-carbamoyl-phenylalaninol compounds and their pharmaceutically useful salts
WO1998017636A1 (en) 1996-10-22 1998-04-30 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
MXPA03007717A (es) 2001-02-27 2005-11-08 Johnson & Johnson Compuestos de carbamato para su uso en la prevencion o tratamiento de trastornos bipolares.
CN1262272C (zh) 2001-02-27 2006-07-05 奥索-麦克尼尔药品公司 用于预防或治疗运动障碍的氨基甲酸酯化合物
ES2262826T3 (es) 2001-02-27 2006-12-01 Ortho-Mcneil Pharmaceutical, Inc. Uso de un compuesto de carbamato en la prevencion o el tratamiento de transtornos de ansiedad.
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
US20050203130A1 (en) 2003-12-02 2005-09-15 Erik Buntinx Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CA2587481A1 (en) 2004-10-28 2006-05-11 Sk Corporation Phenylalkylamino carbamates adjunctive therapy for depression
ES2435403T3 (es) * 2005-06-08 2013-12-19 Sk Biopharmaceuticals Co., Ltd. Tratamiento de trastornos del sueño y vigilia
ES2344469T3 (es) 2005-06-22 2010-08-27 Sk Holdings Co., Ltd. Tratamiento de disfuncion sexual.
AU2005335241B9 (en) 2005-07-26 2012-12-20 Sk Biopharmaceuticals Co., Ltd. Methods for treating substance-related disorders
CA2673487A1 (en) 2006-10-13 2008-04-24 Janssen Pharmaceutica Nv Phenylalkylamino carbamate compositions
KR102173587B1 (ko) 2009-06-22 2020-11-04 에스케이바이오팜 주식회사 피로의 치료 또는 예방 방법
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
MX350745B (es) 2009-11-06 2017-09-14 Sk Biopharmaceuticals Co Ltd * El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia.
US8895609B2 (en) 2009-11-06 2014-11-25 Sk Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
KR102005483B1 (ko) 2012-10-19 2019-07-31 삼성디스플레이 주식회사 박막 트랜지스터 기판 및 그의 수리 방법
US9359290B2 (en) * 2013-03-13 2016-06-07 Jazz Pharmaceuticals International Iii Limited Treatment of cataplexy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2171674C2 (ru) * 1994-10-06 2001-08-10 Сефалон, Инк. Модафинил с определенным размером частиц

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
МОСОЛОВ С.Н. Современные антидепрессанты: механизмы действия и клиническое применение. Фарматека, 2003, №4. Неврология и психиатрия, с.31-40. BLACK J. Medications for the treatment of narcolepsy. Expert Opin. Emerg. Drags., 2001, Oct., №6, c.239-47, он-лайн, [найдено 21.04.2010] [найдено из Интернет] http://www.ncbi.nlm.nih.gov/pubmed/15989524. БЕЛИКОВ В.Г. Фармацевтическая химия. - М.: Высшая школа, 1993, с.43-47. *

Also Published As

Publication number Publication date
TW200716084A (en) 2007-05-01
JP5024635B2 (ja) 2012-09-12
WO2006133393A1 (en) 2006-12-14
AU2006254899B2 (en) 2011-11-24
US12209059B2 (en) 2025-01-28
FR20C1014I1 (https=) 2020-06-12
US20170158622A1 (en) 2017-06-08
CN101217949A (zh) 2008-07-09
US8877806B2 (en) 2014-11-04
US20190367448A1 (en) 2019-12-05
CN101217949B (zh) 2012-10-17
US8440715B2 (en) 2013-05-14
US11753368B2 (en) 2023-09-12
US20090312416A1 (en) 2009-12-17
EP1890684B1 (en) 2013-08-14
NL301037I1 (https=) 2020-04-01
KR101335941B1 (ko) 2013-12-04
US20210078943A1 (en) 2021-03-18
BE2020C004I2 (https=) 2026-01-06
RU2008100019A (ru) 2009-07-20
AU2006254899A1 (en) 2006-12-14
BRPI0613697A2 (pt) 2011-01-25
US9604917B2 (en) 2017-03-28
CA2611713C (en) 2013-10-01
EP1890684A1 (en) 2008-02-27
ES2435403T3 (es) 2013-12-19
CA2611713A1 (en) 2006-12-14
US10351517B2 (en) 2019-07-16
KR20080035565A (ko) 2008-04-23
PL1890684T3 (pl) 2014-05-30
TW201328689A (zh) 2013-07-16
US20130137764A1 (en) 2013-05-30
US20240239740A1 (en) 2024-07-18
TWI419681B (zh) 2013-12-21
NL301037I2 (nl) 2020-05-12
US20250109099A1 (en) 2025-04-03
DK1890684T3 (da) 2013-10-14
JP2008545795A (ja) 2008-12-18
US20140350098A1 (en) 2014-11-27
FR20C1014I2 (fr) 2021-04-23

Similar Documents

Publication Publication Date Title
RU2417077C2 (ru) Способ лечения чрезмерной дневной сонливости (варианты)
JP5901528B2 (ja) 線維筋痛症候群の治療方法
KR101785072B1 (ko) 하지 불안 증후군의 치료방법
JP2013527127A (ja) 注意欠陥／多動性障害（ａｄｈｄ）の治療方法
JP4276838B2 (ja) 疼痛（ｐａｉｎ）の治療における使用のためのカルバメート化合物
JP5271473B2 (ja) 神経障害性疼痛ならびに群発性頭痛および偏頭痛に関連する疼痛の予防もしくは治療における使用のためのカルバメート化合物
JP2009502945A (ja) 覚醒を改善する方法
JP2024522632A (ja) 自閉症スペクトラム障害（ａｓｄ）を治療する方法
RU2303445C2 (ru) Карбаматные соединения для применения для предотвращения или лечения невропатической боли и боли, связанной с кластерной и мигреневой головной болью
HK40102267A (zh) 用於治疗孤独症谱系障碍(asd)的方法
JP2015212288A (ja) 注意欠陥／多動性障害（ａｄｈｄ）の治療方法

Legal Events

Date Code Title Description
PC41 Official registration of the transfer of exclusive right

Effective date: 20120425